Breakthrough fusarium spp fungemia during caspofungin therapy in an abo-incompatible orthotopic liver transplant patient

Journal of Chemotherapy

Volumn 21, Issue 2, 2009, Pages 237-238

  Tascini, C ^a   Urbani, L ^b   Doria, R ^a   Catalano, G ^b   Leonildi, A ^a   Filipponi, F ^b   Menichetti, F ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b CISANELLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CD20 ANTIGEN; CYCLOSPORIN; FLUCONAZOLE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; ITRACONAZOLE; MEROPENEM; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB; TACROLIMUS; TEICOPLANIN; VANCOMYCIN; VORICONAZOLE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ECHINOCANDIN; IMMUNOSUPPRESSIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; ANTIBIOTIC SENSITIVITY; B CELL LYMPHOMA; BLOOD CULTURE; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW BIOPSY; CACHEXIA; CASE REPORT; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMPIRICISM; ENTEROCOCCUS FAECIUM; FEMALE; FEVER; FUNGEMIA; FUNGUS HYPHAE; FUNGUS ISOLATION; FUSARIUM; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKOPENIA; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG LESION; LUNG NODULE; PLEURA EFFUSION; THORAX RADIOGRAPHY; BACTERIAL INFECTION; BLOOD GROUP ABO SYSTEM; DRUG COMBINATION; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; MIDDLE AGED;

ABO BLOOD-GROUP SYSTEM; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; FUNGEMIA; FUSARIUM; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MIDDLE AGED; TEICOPLANIN; THIENAMYCINS;

EID: 67249161469     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.2.236     Document Type: Letter

References (16)

1. Dignani MC, Anaissie EJ. Human fusariosis. Clin Microbiol Infect 2004; 10(Suppl 1): 67-75.
2. Nucci M, Marr KA, Queiros-Tellez F et al. Fusarium infection in hematopoietic stem cell tansplant recipients. Clin Infect Dis 2004; 38: 1237-42
3. Torres HA, Raad II, Kontoyiannis DP. Infections caused by Fusarium species. J Chemother 2003; 15, Suppl.2:28-35.
4. Denning DW, Evans EG, Kibbler CC, et al. Guidelines for the investigation of invasive fungal infection in haematological malignancy and solid organ trasplantation. Eur J Clin Microbiol Infect Dis 1997; 16:424-36.
5. Boutati El, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with haematological malignancy: ten years' experience at a cancer centre and implications for management. Blood 1997;99:999-1008.
6. Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1999;28:7-15.
7. Sampathkumar P, Paya, CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis 2001;32:1237-40.
8. Lodato F, Tame MR, Montagnani M, et al. Systemic fungemia and hepatic localization of Fusarium solani in liver transplant patient: an emerging fungal agent. Liver Transplant 2006;12:1711-4.
9. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR, Rinaldi MG. In vitro activity of voriconazole against selected fungi. Med Mycol 1998;36:239-42.
10. Pujol I, Guarro J, Gene J, Sala J. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp strains. J Antimicrob Chemother 1997;39:239-42.
11. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003; 36:1122-1131.
12. Cudillo L, Girmenia C, Santilli S, et al. Breakthrough fusar-iosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin Infect Dis 2005; 40: 1212-1213.
13. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42:1398-1403.
14. Pfaller MA, Marco F, Messre SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991, against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi. Diagn Microbiol Infect Dis 1998;30:251-5.
15. Apostolidis J, Bouzani M, Platsouka E, et al. Resolution of fungemia due to Fusarium species in a patients with acute leukaemia treated with caspofungin. Clin Infect Dis 2003; 36:1349-1350.
16. Garbino J, Uckay I, Rohner P, Lew D, Van Delden C. Fusarium peritonitis concomitant to kidney transplantation successfully managed with voriconazole: case report and review of the literature. Transplant Int 2005;18:613-8.